More weight-loss drugs offered in type 2 diabetes care shake-up
Having type 2 diabetes means there is too much glucose or sugar in the blood. This makes strokes, heart attacks, heart failure and other health conditions much more of a risk. It is now so common that 10% of the NHS budget goes towards treating it.NICE, which produces guidance for the NHS on how to give patients the best care, recommends a move away from a "one size fits all" approach and towards more personalised treatment.It is calling for newer diabetes medicines called SGLT-2 inhibitors, which protect the heart and kidneys as well as lowering blood sugar levels, to become the first-choice treatment for all diabetes patients. Around 2.3 million people will be eligible for these drugs.Some 22,000 lives could be saved if 90% of all diabetes patients were prescribed them, NICE says, but access is not equal across the UK. There is evidence that women, older people and black people are less likely to be prescribed them."There is some urgency to find ways to increase the uptake of SGLT-2 inhibitors because if we were to achieve perfect uptake, the nation would be significantly healthier," said Dr Waqaar Shah, chair of the guideline committee.Only one in five people with type 2 diabetes and cardiovascular disease are currently prescribed the medicines.Prescribing the tablets to more people would particularly benefit those living in poorer areas and ethnic minorities, NICE says.
Under the guidance, which is still at a draft stage and needs to go through a consultation, around 750,000 more people with type 2 diabetes will be offered GLP-1 agonists such as semaglutide and liraglutide, which have become very popular as the drugs contained in weight-loss jabs.Adults with cardiovascular disease and some who develop type 2 before they are 40 are the groups recommended to be offered them.These drugs can be used both to lower blood sugar levels and to support some people with weight loss.Prof Jonathan Benger, deputy chief executive and chief medical officer at NICE, said the updated guidance was "a significant evolution" in type 2 diabetes treatment which could help prevent heart attacks, strokes and other serious complications before they happen."This guidance means more people will be offered medicines, where it is right to do so, to reduce their future risk of ill health," he added.The guidelines are part of a long-term plan by the NHS in England to reduce health inequalities and focus on preventing ill health in the first place.The charity Diabetes UK said the announcement propelled type 2 diabetes treatments "into the 21st century"."These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes," said Douglas Twenefour, head of clinical at the charity.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ITV News
32 minutes ago
- ITV News
New treatment for advanced bladder cancer 'which doubles survival time'
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. 'It was horrific': UK hair transplant patients left disfigured and scarred Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
Scottish Sun
32 minutes ago
- Scottish Sun
New treatment for devastating cancer that DOUBLES survival rate to be rolled out on NHS
'I am going to have an extra few years to see my grandson grow up and maybe even be around to see him get married,' Martyn, who took the new treatment, says 'FIRST IN DECADES' New treatment for devastating cancer that DOUBLES survival rate to be rolled out on NHS Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) THOUSANDS of Brits with bladder cancer could survive for twice as long after a new treatment is given the green light to be dished out on the NHS. Health chiefs have said the approval marks "one of the most hopeful advances in decades for people with bladder cancer". Sign up for Scottish Sun newsletter Sign up 3 In the UK, around 10,500 people are diagnosed with bladder cancer each year Credit: Getty They said there had been real 'unmet need' for patients with the advanced form of the disease. With bladder cancer, up to 29 per cent of people are diagnosed at stage 4, when it has already spread, and only survive for around a year after diagnosis. The treatment is a combination of enfortumab vedotin, an antibody drug made by Astellas and Pfizer, and pembrolizumab, made by Merck. It was approved for use by the National Institute for Health and Care Excellence (Nice) yesterday, which means it can now be used on the NHS for people with bladder cancer. The combination, when tested in clinical trials, gave patients and average of 33.8 months compared with 15.9 months while having chemotherapy. Scientists have also measured the amount of time people that survived without their disease getting worse. They found that those on the treatment had a progression-free survival time of a year compared with six months for those receiving standard treatment. Three in ten patients had no evidence of cancer remaining after the treatment, compared with 14.5 per cent of patients receiving standard care. Martyn Hewett, 75, from Stratford, East London, received the new treatment at Barts Health NHS Trust, after surgery to remove his tumours failed. He said: "I feel very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. The signs and symptoms of cancer "Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said 'most people in your position live for a year', and now, three-and-a-half years later, here I am. "I am going to have an extra few years to see my grandson grow up and maybe even be around to see him get married." The treatment is given via an IV infusion to those whose cancer has spread around their body and cannot be surgically removed. The first drug, enfortumab vedotin, directly targets the cancer cells and kills them, while pembrolizumab helps the immune system to recognise and fight any remaining cancer cells. As well as experiencing better survival rates, patients also have fewer harmful side-effects. About 10,500 people in the UK are diagnosed with bladder cancer each year. The new treatment should help about 1,250 patients annually. Helen Knight, director of medicines evaluation at Nice, said: "This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives." 3 Martyn Hewett, from London, received the treatment at Barts Health NHS Trust, after a surgery to remove his tumours failed Credit: PA 3 Martyn believes the treatment has given him an extra few years with his grandson Credit: PA Professor Peter Johnson, NHS England's national clinical director for cancer, said: "This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival. "Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks and our rollout to NHS patients will make a huge difference to the lives of those affected and their families." Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: "This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available." What causes bladder cancer? The exact causes are unknown, but there are a number of things that can increase your risk factor. Like with many cancers, bladder cancer appear to be caused by exposure to harmful substances, which lead to abnormal changes in the bladder's cells over many years. Tobacco smoke is a common cause and it's estimated that more than one in three cases of bladder cancer are caused by smoking. Contact with certain chemicals previously used in manufacturing is also known to cause bladder cancer. However, these substances have since been banned
The Sun
33 minutes ago
- The Sun
Urgent warning over ‘toxic' water at UK beauty spot after dog mysteriously dies with owners urged to ‘keep eyes peeled'
DOG warners have been urged to keep their eyes peeled after a pooch died at a popular tourist spot. The pet showed symptoms of toxic exposure when it visited the much loved walking route before it passed away. 3 3 The Broadwater is a beautiful saltwater lagoon just two miles from Tywyn, Wales, which is a hotspot for tourists and hikers. Formed when the Dysynni estuary stiled up in the 19th century, it is a Site of Special Interest and is surrounded by verdant grassland and sweeping salt marshes. However, holidaymakers and pet owners are now being urged to stay away after the death of a dog was linked to the site. According to Williams Veterinary Surgeons, located in Tywyn, the dog passed away on August 15, after visiting The Broadwater. Although blood testing wasn't possible, the pet's symptoms matched those of toxic exposure. A spokesperson for Williams Veterinary Surgeons said: 'At this time of year we typically see a lot of summer bugs at Broadwater because it is a popular area for walking dogs. 'On this occasion, it was much more serious and out of the ordinary. 'The dog's owners were keen that we make people aware of the need to keep their eyes peeled when in walking dogs in this area.' Locals flocked to social media to pay tribute to the dog, though some claimed that this isn't the first time that a dog has died after visiting The Broadwater. One dog owner said: 'This makes me so sad. 'It's not the first time this has happened either. 'I lost my girl within the space of 24 hours from something she picked up there. 'My dad's dog was extremely (like, very very scarily) unwell at the same time – they both walked together daily. Only place they could have picked anything up was down there.' Another pet owner also claimed that they had lost a pet after visiting the Broadwater. The social media user said: 'This is not the first time a dog has died from being on that land. 'I have tried for years to understand why dogs get ill or die from being down at the Broadwaters. 'I nearly lost my dog a few years ago after he drank from a puddle down there.' Williams Vets is now asking dog walkers to avoid the area. 3 If dog owners visit the Broadwater, Williams Vets has urged them to report anything that seems suspicious. Tywyn Town Council and Cyngor Gwynedd (Gwynedd Council) has been contacted for comment by The Sun. The news comes after dangerous toxic blobs washed up on the shores of Anglesey. The congealed chunks of palm oil were described as looking like 'earwax' and can absorb chemicals and sewage. If eaten by a dog, they can cause serious infections leading to diarrhoea and pancreatitis. HM Coastguard has warned dog owners to keep an eye out for any suspicious pebbles, which have a waxy quality or give off a strong smell. If your dog eats one, it is important to take them to a vet.
